Company Filing History:
Years Active: 1983
Title: A Kirk Field: Innovator in Pharmaceutical Compositions
Introduction
A Kirk Field is an accomplished inventor based in North Wales, PA, USA. He is recognized for his significant contribution to the field of pharmaceuticals with a focus on antiviral compositions. His expertise has led him to develop innovative solutions that enhance the effectiveness of antiviral therapies.
Latest Patents
Field holds a notable patent for a pharmaceutical composition that features a complex of polyriboinosinic-polyribocytidylic acid (poly I:C) modified with poly-L-lysine hydrobromide. This innovative composition is characterized by its increased resistance to hydrolysis by pancreatic ribonuclease, making it 5-15 times more durable than the parent poly I:C. Notably, this pharmaceutical solution achieves significant levels of serum interferon induction in monkeys when administered, demonstrating effectiveness where poly I:C alone shows minimal response. The formulation, designated poly I:C/poly-L-lysine, requires no special solubilizing agents, streamlining the preparation process for high-concentration solutions.
Career Highlights
Field is affiliated with Merck & Company, Inc., a leading global healthcare company known for its contributions to pharmaceuticals and innovation. His work underscores the company's commitment to advancing healthcare through innovative solutions. Field's accomplishments reflect a dedication to improving therapeutic outcomes through rigorous research and development.
Collaborations
Throughout his career, A Kirk Field has collaborated with notable colleagues such as Alfred A. Tytell and George P. Lampson. These partnerships showcase the collaborative nature of research in the pharmaceutical field, fostering the exchange of ideas and expertise to drive innovative developments.
Conclusion
A Kirk Field's contributions to pharmaceutical science represent a significant advancement in antiviral treatments. Through his patent for poly I:C/poly-L-lysine, he has not only demonstrated innovation but also the potential for improved patient outcomes in antiviral therapies. His career at Merck & Company, Inc. reflects a commitment to excellence in research and collaboration within the scientific community.